Related Experiment Video
Updated: Dec 21, 2025
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
Maria B Garcia-Fabiani1,2, Maria Ventosa1,2, Andrea Comba1,2
1Department of Neurosurgery, University of Michigan Medical School , Ann Arbor, MI, USA.
Introduction:
Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy, and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.
Areas Covered:
The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations, and key challenges. They also examine promising approaches under preclinical development.
Expert Opinion:
In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles.
Insights
Immunotherapies show promise for treating malignant glioma by enabling immune cells to attack tumors. However, clinical trials face challenges due to complex tumor microenvironments and treatment variables, necessitating further research.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Gliomas are aggressive brain tumors with poor prognoses despite standard treatments.
- The immunosuppressive tumor microenvironment hinders effective anti-tumor immune responses.
- Novel immunotherapeutic strategies are being developed to overcome these challenges.
Purpose of the Study:
- To review current immunotherapeutic strategies for glioma in clinical trials.
- To examine the mechanisms, limitations, and challenges of these therapies.
- To explore promising preclinical immunotherapeutic approaches for glioma.
Main Methods:
- Review of phase-I/II clinical trials for glioma immunotherapies.
- Analysis of preclinical studies on novel immunotherapeutic strategies.
- Discussion of mechanisms of action, limitations, and challenges.
Main Results:
- Sophisticated immunotherapeutic strategies have shown success in preclinical glioma models.
- Clinical trials have not yet produced consistent positive results for glioma patients.
- Key challenges include understanding immune cell interactions, treatment timing, and combination therapies.
Conclusions:
- Despite challenges, advancements in immunotherapy offer new avenues for treating malignant glioma.
- Further research is needed to optimize treatment strategies and overcome hurdles in clinical application.
- Emerging alternatives aim to bypass current limitations in glioma immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:28Preclinical Development: Overview